UVA Licensing & Ventures Group

What UVA Licensing & Ventures Group does

UVA Licensing & Ventures Group (LVG) is the technology transfer and venture development office of the University of Virginia, operating as a department within a public state university rather than an independent for-profit entity. Headquartered at 722 Preston Avenue, Suite 107 in Charlottesville, LVG partners with UVA faculty, researchers, and graduate students to commercialize university research through invention disclosure, patent prosecution, licensing negotiation, startup formation, and direct seed investment. Service delivery is structured around four programs: Technology Transfer (invention disclosure and patenting, provided free of charge to UVA inventors), the UVA LVG Seed Fund (a second $10 million fund deployed for early-stage UVA startup investments), Enterprise Studio (a partnership with UVA Innovates for commercialization support), and the I-Corps Program (NSF-funded customer-discovery training delivered through the eight-university Mid-South I-Corps Hub).

LVG's commercialized portfolio spans medical devices, therapeutics, agricultural biotechnology, life-sciences tools, and analytics. Headline technologies include the artificial pancreas algorithm (developed by Marc Breton and Boris Kovatchev, licensed to Tandem Diabetes Care as t:slim X2 with Control-IQ, now used by 400,000+ patients worldwide), focused ultrasound for essential tremor and Parkinson's disease (pioneered by Dr. Jeff Elias, FDA-approved 2016), the Lacripep synthetic peptide for neurotrophic keratitis (TearSolutions, FDA Orphan Drug and Fast Track Designations, Phase 2 dosing initiated 2026), AgroSpheres' bioparticle platform (multi-year Bayer collaboration and Albemarle County manufacturing facility), BrightSpec's Molecular Rotational Resonance spectrometry ($18.4M Series C led by Genoa Ventures and Arboretum Ventures), and Ceres Nanosciences' Nanotrap particles (commercialized through Promega Corporation for wastewater-based surveillance).

Revenue is generated primarily through licensing royalties on agreements such as the Tandem Diabetes Care deal and the historical Adenocard drug (which has returned $50M+ to UVA cardiovascular research over 30 years), supplemented by gains from successful seed-fund exits (notably TypeZero Technologies' acquisition by DexCom in 2018) and reinvestment back into UVA research and the seed fund. The office is funded primarily through the University of Virginia's institutional budget and does not charge researchers for its core services. Geographic operating scope is regional (Charlottesville and Central Virginia), with portfolio companies generating global commercial reach through their licensee partners.

Name

UVA Licensing & Ventures Group

Legal name

UVA Licensing & Ventures Group

Website

https://lvg.virginia.edu

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

UVA Licensing & Ventures Group is the University of Virginia's technology transfer office, partnering with UVA faculty, researchers, and students to commercialize innovations through patenting, licensing, startup formation, and a $10 million seed fund. Its portfolio spans medical devices, therapeutics, agricultural biotechnology, and life-sciences tools.

Ownership category

akta.pro rank

Product category

Technology Transfer and Commercialization Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Corporate Deep Tech / R&D Commercialization CVC (FSANAHAL)

akta.pro secondary industry

Corporate Innovation & Technology Scouting Units (with investment mandate) (FSANAHAI)

Keywords

• Technology transfer services
• University intellectual property licensing
• Invention disclosure management
• Seed fund investments
• Startup commercialization support

Headquarters

HQ city

Charlottesville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Licensing Royalties: UVA LVG generates revenue through licensing fees and royalties from technologies commercialized by companies. Examples include royalties from the artificial pancreas technology licensed to Tandem Diabetes Care and revenue from the Adenocard drug commercialized over 30 years ago.
2. Seed Fund Investment Returns: The LVG Seed Fund makes investments in UVA-born startup companies. Returns from successful exits like TypeZero Technologies (acquired by DexCom) generate returns that are reinvested into the university for continued research.
3. Federal Funding Support: While not direct revenue, LVG helps connect researchers to federal funding sources including NSF, NIH, and DOE that support technology development and commercialization activities.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

UVA Licensing & Ventures Group (LVG) is the University of Virginia's technology transfer office that partners with faculty, researchers, and investors to bring innovations discovered at UVA to the marketplace. Its core services include invention disclosure intake, patent management and prosecution, marketing of technologies, licensing negotiation, startup formation, and seed-stage funding through the UVA LVG Seed Fund. It also runs the Enterprise Studio commercialization support program and the I-Corps entrepreneurship training program.

Product overview

UVA Licensing & Ventures Group (LVG) is the University of Virginia's technology transfer office that partners with faculty, researchers, and investors to commercialize innovations discovered at UVA. LVG offers a comprehensive suite of services including Technology Transfer (invention disclosure, patenting, licensing), the UVA LVG Seed Fund (managing $10M+ in investments), Enterprise Studio (startup formation support), and the I-Corps Program (entrepreneurship training). LVG maintains a portfolio of venture companies spun out from UVA research, and administers the annual Edlich-Henderson Innovator of the Year award. Their ventures portfolio includes companies in biotechnology (TearSolutions, Hyku Biosciences), agricultural technology (AgroSpheres, Lytos Technologies), medical devices (Nanochon, artificial pancreas), analytics (Astraea, BrightSpec), and pharmaceuticals (Adial Pharmaceuticals, Slate Bio).

Differentiator

Problem solved

Functional benefit

Brands

• I-Corps Mid-South Hub: Regional I-Corps program at UVA that provides entrepreneurship training for faculty, researchers, and students to help evaluate the market potential of technologies.
• UVA LVG Seed Fund
• Enterprise Studio

Products and services

• Technology Transfer Services
• UVA LVG Seed Fund
• Enterprise Studio
• I-Corps Program

Quantifiable outcome

• 400,000+ people benefit from artificial pancreas technology globally
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Partnerships

13 partnerships are on record, tiered core and flagship.

• TearSolutionscoreStrategic or Co-development Partner · 2 June 2026Clinical-stage biotechnology company developing Lacripep for neurotrophic keratitis. Received FDA Orphan Drug and Fast Track Designations. Phase 2 trial initiated.
• BayerflagshipStrategic or Co-development Partner · 5 May 2023Multi-year collaboration with AgroSpheres to create novel modalities of biologicals for use as crop protection products. AgroSpheres obtained early patents through LVG.
• Promega CorporationcoreTechnology or Integration · 25 January 2023Promega launched new purification system including Ceres Nanosciences' Nanotrap particles for wastewater-based epidemiology. The partnership enables labs to purify pathogen nucleic acids from wastewater samples.
• NSF Mid-South Innovation Corps HubflagshipStrategic or Co-development Partner · 27 September 2022UVA is one of eight universities in the NSF-funded Mid-South I-Corps Hub led by Vanderbilt University. The consortium aims to enhance innovation capacity, support promising research, and accelerate translation of discoveries into solutions. Each hub receives up to $3 million for five years.
• UVA Innovates (Enterprise Studio)coreStrategic or Co-development PartnerEnterprise Studio is a partnership between LVG and UVA Innovates that supports faculty, research staff, and graduate student researchers who are considering commercializing their UVA-based ideas and inventions.
• CvilleBioHubcoreStrategic or Co-development PartnerIndependent nonprofit organization whose mission is to accelerate the biotechnology industry in Central Virginia. Received $548,000 GO Virginia grant for biotechnology innovation cluster growth.
• Focused Ultrasound FoundationcoreStrategic or Co-development PartnerCharlottesville-based foundation that has been a longtime supporter of UVA Health's focused ultrasound research and helped launch the world's first focused ultrasound cancer immunotherapy center.
• Darden School of Business i.Lab IncubatorcoreStrategic or Co-development PartnerAgroSpheres was incubated at the Darden i.Lab Incubator, demonstrating cross-school collaboration within UVA's entrepreneurial ecosystem.
• Vanderbilt University (Wond'ry)coreStrategic or Co-development PartnerLeads the NSF Mid-South I-Corps Hub. The Wond'ry is Vanderbilt's Innovation Center that will direct the hub.
• Planet Labs PBCcoreTechnology or IntegrationSatellite imagery provider partnership with LVG portfolio company Astraea. Astraea provides access to Planet's tasking capabilities within its spatiotemporal analytics platform.
• UVA School of MedicinecoreStrategic or Co-development PartnerMajor source of innovations commercialized through LVG, including artificial pancreas, focused ultrasound, and various cancer therapeutics.
• UVA School of Engineering and Applied SciencecoreStrategic or Co-development PartnerKey source of engineering and applied science innovations including Nanochon's cartilage implant and AgroSpheres' bioparticle technology.
• Lytos TechnologiescoreStrategic or Co-development PartnerUVA startup founded in 2018 by Professor Bryan Berger (2025 Innovator of the Year) to commercialize patented biofungicide technology for food safety and agricultural protection.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Wisconsin Alumni Research Foundation (WARF): WARF is one of the oldest and largest university technology transfer organizations, patenting and licensing University of Wisconsin discoveries and funding early-stage research. Comparable in scope and longevity to UVA LVG.
• Johns Hopkins Technology Ventures: Johns Hopkins' tech transfer arm managing patents, licensing, startup formation, and a ventures fund across a strong biomedical research base. Directly comparable function and portfolio composition to LVG.
• Duke Office of Licensing & Ventures: Duke's technology transfer and ventures office handles invention disclosures, licensing, startups, and seed-stage investment. Direct operational counterpart to UVA LVG with overlapping life sciences and engineering research focus.
• Stanford Office of Technology Licensing: Stanford's TLO managing invention disclosures, patent prosecution, licensing, and equity administration for one of the highest-volume university research pipelines. Closest structural peer to LVG, executing the same invention-to-license workflow.
• MIT Technology Licensing Office: MIT's central technology transfer office that licenses MIT-derived IP, supports startup formation, and operates innovation programs. Direct functional analog to UVA LVG at a larger research university, executing the same mission of patent management, licensing, and venture formation.
• Caltech Office of Technology Transfer and Corporate Partnerships: Caltech's TTO manages invention licensing, patent prosecution, and startup formation across high-science research output. Comparable in mission and in the depth of biomedical/engineering IP to UVA LVG.
• Columbia Technology Ventures: Columbia University's tech transfer office that protects and licenses inventions, supports faculty-led startups, and runs an seed/venture program. Directly comparable in mission scope and service model to UVA LVG.
• University of Michigan Office of Technology Transfer: UM's TTO handles invention disclosures, patenting, licensing, and startup support across a major research university. Equivalent functional role to LVG in a similarly large public research university.
• Yale Ventures: Yale's combined innovation and technology transfer organization supporting faculty startups, licensing Yale IP, and operating programs akin to I-Corps and seed funding. Direct peer in structural mandate.

Broad incumbents

• In-Q-Tel: Strategic deep-tech investor (CIA-affiliated CVC) sourcing, funding, and commercializing R&D-derived technologies across universities and national labs. Broader incumbent in the same R&D commercialization space that LVG occupies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/user/uvainnovation
• LinkedInlinkedin.com/company/university-of-virginia

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments18 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UVA Licensing & Ventures Group